Mitratapide

Mitratapide is a veterinary medication used for the treatment of overweight and obese dogs sold under the brand name Yarvitan. Its mechanism of action involves inhibition of microsomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietary lipids.^[3] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.^[4]

Mitratapide

Clinical data
Trade names	Yarvitan
Other names	Mitratapid; R103757
Routes of administration	By mouth
ATCvet code	QA08AB90 (WHO)
Legal status
Legal status	CA: ℞-only
Pharmacokinetic data
Bioavailability	55–69%
Protein binding	>99.9%[1]
Metabolism	Extensive liver (sulfoxidation); first pass effect
Elimination half-life	6.3 hours (mitratapide), up to 44.7 hours (metabolites)
Excretion	Feces (80–90%)[2]
Identifiers
IUPAC name 2-[(2R)-Butan-2-yl]-4-[4-[4-[4-[[(2S,4R)-2-(4-chlorophenyl)-2-[(4-methyl-1,2,4-triazol-3-yl)sulfanylmethyl]-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
CAS Number	179602-65-4
PubChem CID	213047
ChemSpider	184740
UNII	FVW7T75XP4
KEGG	D05060
CompTox Dashboard (EPA)	DTXSID801016298
Chemical and physical data
Formula	C36H41ClN8O4S
Molar mass	717.29 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC[C@@H](C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@@H]5CO[C@@](O5)(CSC6=NN=CN6C)C7=CC=C(C=C7)Cl
InChI InChI=1S/C36H41ClN8O4S/c1-4-26(2)45-35(46)44(25-39-45)31-11-9-29(10-12-31)42-17-19-43(20-18-42)30-13-15-32(16-14-30)47-21-33-22-48-36(49-33,27-5-7-28(37)8-6-27)23-50-34-40-38-24-41(34)3/h5-16,24-26,33H,4,17-23H2,1-3H3/t26-,33-,36-/m1/s1 Key:HQSRVYUCBOCBLY-XOOFNSLWSA-N

The drug was developed by Janssen Pharmaceutica and is chemically related to the antifungal drugs such as itraconazole which were also developed by Janssen.

Mitratapide (under the brand name Yarvitan) was authorized for use in the EU by the European Medicines Agency for helping weight loss in dogs, but it has since been withdrawn from the market in the EU.^[5]